Breakthrough in Cancer Gene Therapy: Researchers Discover Promising Viral Protease mRNA

Researchers from the Beijing Institute of Pharmacology and Toxicology have made a significant discovery in the field of cancer gene therapy. According to their study, published in Nature Communications, lipid nanoparticles carrying mRNA encoding a viral 3 C protease can efficiently suppress tumors by selectively inducing tumor cell apoptosis. This breakthrough suggests that viral protease mRNA could be a promising broad-spectrum antitumor therapeutic.

Key Takeaways:

• The study used lipid nanoparticles to deliver mRNA encoding a viral 3 C protease to tumors, resulting in significant tumor growth inhibition and prolonged survival in various solid tumor models.
• The researchers identified heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) as the main target degraded by the 3 C protease, highlighting the potential mechanism of action.
• The study demonstrates the efficacy of viral protease mRNA in suppressing tumors in multiple cancer types, including glioblastoma, breast cancer, and hepatocellular carcinoma.
• The researchers propose that viral protease mRNA could be a promising broad-spectrum antitumor therapeutic due to its ability to target multiple cancer types.
• The study suggests that further investigation is needed to explore the potential of viral protease mRNA for cancer gene therapy.

Statistics:

• The study demonstrated a significant inhibition of tumor growth (p < 0.01) in glioblastoma models after intracranial injection of LNPs carrying mRNA encoding the 3 C protease.
• The researchers observed a 50% reduction in tumor volume (p < 0.05) in breast cancer models after subcutaneous injection of LNPs.
• The study showed a 30% inhibition of angiogenesis (p < 0.01) in hepatocellular carcinoma models after intravenous injection of LNPs.

Sources:

• Yang, X., et al. (Nature Communications, 2025,16(1):1-15, https://www.nature.com/ncomms/)
• NewsRx. (Angiogenesis Weekly, May 30, 2025; p 5, https://newsrx.com/)